Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

open", "step towards", "planned", "believes", "expected", "developing", or variations thereon, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation, the Company's need for additional capital, which may not be available in a timely manner or at all and which, if not obtained, will have a material adverse impact on the Company and its ability to continue; uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; uncertainty whether planned clinical trials will occur as expected or whether such trials, as well as the ongoing clinical trial in Sweden and Germany, will be successful; product liability and insurance risks; research and development risks, the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, including its latest Annual Information Form, at http://www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, opinio
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... This is a professional and in-depth study ... industry in Global and China. The report provides a ... industry chain structure. Global market analysis and Chinese domestic ... developments, trends and competitive landscape of the market. A ... offered. , The report also focuses on development policies ...
(Date:9/22/2014)... , Sept. 22, 2014 Research ... "Global and Chinese Microcrystalline Cellulose Industry Report 2014" ... Global and Chinese Microcrystalline Cellulose Industry Report 2014 is ... of the global microcrystalline cellulose industry with a focus ... a basic overview of the industry including definitions, classifications, ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/21/2014)... at the University of Basel in Switzerland have ... a charged molecule for the first time. These ... measurements of molecular properties and may also contribute ... technology. The results were published in the scientific ... study of the interaction between matter and light, ...
Breaking Biology Technology:m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Uncovering the forbidden side of molecules 2
... Inc. (OTC Bulletin Board: NWBO ) (NW Bio) joined ... over the course of more than 13 months, the parties ... brain cancer in Germany. As a result, the Company is ... with both its clinical trial program and Hospital Exemption cases ...
... J.D., will offer her expert perspective on  the ... she presents "EHRs: Meaningful Use & Beyond" during ... held  April 24-26, 2012, at the Thelma Keller ... During the presentation, Pita, who serves as executive ...
... facilitated the evolution and complexity of terrestrial organisms, including human ... by those organisms, which in turn were able to generate ... oxygen molecules work inside the body, more attention is being ... to thwart them. A number of environmental ...
Cached Biology Technology:Northwest Bio and Fraunhofer IZI Announce Milestones Reached 2Northwest Bio and Fraunhofer IZI Announce Milestones Reached 3Northwest Bio and Fraunhofer IZI Announce Milestones Reached 4Prognosis HIS Executive Slated To Offer EHR Advice At Illinois Rural Health Association Conference 2Avocado Oil: The 'Olive Oil Of The Americas'? 2Avocado Oil: The 'Olive Oil Of The Americas'? 3Avocado Oil: The 'Olive Oil Of The Americas'? 4
(Date:9/22/2014)... key molecular cog in a plant,s biological clock ... based on temperature. , Transcription factors, or genetic switches, ... such as light, rain, soil quality, or even ... USC has isolated one, called FBH1, that reacts to ... needed while in keeping it on a consistent track. ...
(Date:9/22/2014)... the Society of Environmental Toxicology and Chemistry (SETAC) held ... prioritize the scientific research needed to understand the risks ... environment. The effort was extended, and results were ... international journal, Integrated Environmental Assessment and Management ... podcast interviewing the lead author of the study, Murray ...
(Date:9/22/2014)... YORK CITY (September 22, 2014)The Brain & ... the award of NARSAD Young Investigator Grants ... 200 of the world,s most promising young ... for groundbreaking neurobiological research will seek to ... strategies for psychiatric disorders that affect one ...
Breaking Biology News(10 mins):Genetic switch regulates a plant's internal clock based on temperature 2Priorities for research on pharmaceutical and personal care products in the environment 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2
... new use as an adjuvant to cancer therapy, providing an ... study published in the Feb. 15 issue of Clinical Cancer ... Gallez, Ph.D., professor of pharmacy at the Université de Louvain ... A into two types of mouse tumors, the tumors' cellular ...
... H5N1 influenza samples in Southeast Asia shows not only ... are related but also that they belong to two ... for Disease Control and Prevention report their findings today ... "As the virus continues its geographic expansion, it is ...
... in Africa declared that a dramatic rise in tuberculosis (TB) ... TB case notifications have increased as much as four-fold over ... HIV. When individuals are infected with both HIV and TB, ... to active TB. , To combat the problem, the ...
Cached Biology News:Botox could help target resistant tumors for treatment 2Botox could help target resistant tumors for treatment 3Study outlines genetic differences between potential pandemic influenza strains 2
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Biology Products: